Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jul 23, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The MMML Predict trial is studying a new tool that can help doctors better understand how likely it is for patients with Diffuse Large B Cell Lymphoma (DLBCL) to respond to their initial treatment. This tool aims to identify patients who may be at a very high risk of treatment not working, allowing for early intervention and better care. The trial is currently looking for participants aged 18 and older who have been diagnosed with DLBCL and are set to start standard treatment. Participants must be able to give their consent and have no other active cancers or certain health issues, like active HIV.
If you join this trial, you will be part of an important effort to improve the way doctors predict treatment outcomes for DLBCL patients. You will receive standard care while contributing to research that could help many others in the future. Your participation could make a difference in how this disease is treated and understood.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Histological diagnosis of DLBCL\&LBCL
- • 2. Planned treatment with guideline-based first-line therapy
- • 3. Patient's consent
- • 4. All genders, Patient age ≥ 18 years
- • 5. Ability to consent
- Exclusion Criteria:
- • 1. Treatment with R-CHOP/-like regimens already started
- • 2. Relationship of dependence/ direct employment with the investigator
- • 3. Active HIV-infection
- • 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
About University Medical Center Goettingen
The University Medical Center Göttingen (UMG) is a leading academic institution in Germany, renowned for its commitment to advancing medical research and education. As a sponsor of clinical trials, UMG leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research that aims to improve patient care and treatment outcomes. With a focus on interdisciplinary collaboration, UMG fosters partnerships across various medical fields, ensuring a comprehensive approach to clinical investigation. Its dedication to ethical standards and patient safety underscores its role in translating scientific discoveries into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göttingen, Lower Saxony, Germany
Patients applied
Trial Officials
Lorenz Trümper
Principal Investigator
PI of the study
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported